ABUS vs UPST · P/E 5.4, rev $6.2M vs P/E 74, rev $636.5M
Arbutus Biopharma Corp (ABUS) versus Upstart Holdings Inc (UPST) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Upstart Holdings Inc (UPST) is a credit services company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported UPST revenue for 2024-12-31 was $636.5M. Net income was -$128.6M. Revenue was up 23.9% from 2023-12-31 to 2024-12-31. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. UPST currently screens at market cap $2.92B and trailing P/E 74.3.
Not investment advice. Open the ABUS and UPST stock pages for the full models.
Not investment advice.